Search Results

Planatome, a medical device company that applies atomic-level polishing from the semiconductor industry to create advanced surgical blades that lead to better patient outcomes, announced a new study published in the Journal of Craniofacial Surgery.

Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the “Merger Agreement”), effective immediately.

Blade Therapeutics, Inc. announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.

The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.

Blade Therapeutics, Inc. (Blade) today announced with profound sadness the unexpected passing of company General Counsel and Secretary Alan C. Mendelson on October 8, 2021, in San Francisco.

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the “Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need” panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET).

Biotech Acquisition Company (Nasdaq: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., announced today that they have entered into a definitive merger agreement.

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, announced the presentation of positive data from Phase 1 and preclinical studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.